- Home
- KRC vs EWTX Comparison
KRC vs EWTX Comparison
Compare KRC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | EWTX |
|---|---|---|
| Founded | 1947 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KRC | EWTX |
|---|---|---|
| Price | $36.23 | $39.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 14 |
| Target Price | $39.57 | ★ $52.62 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ 31.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,112,667,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.36 | $15.94 |
| 52 Week High | $43.58 | $48.51 |
Technical Indicators
Market Signals| Indicator | KRC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 48.47 |
| Support Level | $35.88 | $38.43 |
| Resistance Level | $37.45 | $41.22 |
| Average True Range (ATR) | 1.16 | 1.71 |
| MACD | 0.35 | 0.28 |
| Stochastic Oscillator | 62.91 | 76.31 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.